Literature DB >> 30838863

Surfactant plus budesonide decreases lung and systemic inflammation in mechanically ventilated preterm sheep.

T Brett Kothe1, Matthew W Kemp2, Augusto Schmidt3, Emily Royse1, Fabrizio Salomone4, Michael W Clarke5, Gabrielle C Musk2,6, Alan H Jobe2,3, Noah H Hillman1.   

Abstract

Mechanical ventilation with normal tidal volumes (VT) causes lung and systemic inflammation in preterm sheep. Mechanical ventilation is associated with bronchopulmonary dysplasia (BPD) in preterm infants, and the addition of budesonide to surfactant decreases BPD in clinical trials. Budesonide with surfactant will decrease the lung injury from mechanical ventilation for 24 h in preterm sheep. Lambs at 126 ± 1 day gestational age were delivered and randomized to either: 1) surfactant (200 mg/kg) or 2) surfactant mixed with budesonide (0.25 mg/kg) before mechanical ventilation with VT of 7-8 ml/kg for 2, 6, or 24 h (n = 6 or 7/group). Lung physiology and budesonide levels in the plasma and the lung were measured. Lung tissue, bronchoalveolar lavage fluid (BALF), liver, and brain tissues were evaluated for indicators of injury. High initial budesonide plasma levels of 170 ng/ml decreased to 3 ng/ml at 24 h. Lung tissue budesonide levels were less than 1% of initial dose by 24 h. Although physiological variables were generally similar, budesonide-exposed lambs required lower mean airway pressures, had higher hyperoxia responses, and had more stable blood pressures. Budesonide decreased proinflammatory mRNA in the lung, liver, and brain. Budesonide also decreased total protein and proinflammatory cytokines in BALF, and decreased inducible nitric oxide synthase activation at 24 h. In ventilated preterm lambs, most of the budesonide left the lung within 24 h. The addition of budesonide to surfactant improved physiology, decreased markers of lung injury, and decreased systemic responses in liver and brain.

Entities:  

Keywords:  bronchopulmonary dysplasia; lung inflammation; prematurity

Mesh:

Substances:

Year:  2019        PMID: 30838863      PMCID: PMC6589588          DOI: 10.1152/ajplung.00477.2018

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  24 in total

Review 1.  Recent advances in our understanding of the mechanisms of late lung development and bronchopulmonary dysplasia.

Authors:  David E Surate Solaligue; José Alberto Rodríguez-Castillo; Katrin Ahlbrecht; Rory E Morty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-09-28       Impact factor: 5.464

2.  In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.

Authors:  Francesca Ricci; Chiara Catozzi; Francesca Ravanetti; Xabier Murgia; Francesco D'Aló; Natalia Macchidani; Elisa Sgarbi; Valentina Di Lallo; Federica Saccani; Marisa Pertile; Antonio Cacchioli; Silvia Catinella; Gino Villetti; Maurizio Civelli; Francesco Amadei; Fabio Franco Stellari; Barbara Pioselli; Fabrizio Salomone
Journal:  Pediatr Res       Date:  2017-08-23       Impact factor: 3.756

3.  Intratracheal Administration of Budesonide/Surfactant to Prevent Bronchopulmonary Dysplasia.

Authors:  Tsu F Yeh; Chung M Chen; Shou Y Wu; Zahid Husan; Tsai C Li; Wu S Hsieh; Chang H Tsai; Hung C Lin
Journal:  Am J Respir Crit Care Med       Date:  2016-01-01       Impact factor: 21.405

4.  Effects of budesonide and surfactant in preterm fetal sheep.

Authors:  T Brett Kothe; Emily Royse; Matthew W Kemp; Augusto Schmidt; Fabrizio Salomone; Masatoshi Saito; Haruo Usuda; Shimpei Watanabe; Gabrielle C Musk; Alan H Jobe; Noah H Hillman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-04-19       Impact factor: 5.464

5.  Pulmonary and systemic expression of monocyte chemotactic proteins in preterm sheep fetuses exposed to lipopolysaccharide-induced chorioamnionitis.

Authors:  Tushar A Shah; Noah H Hillman; Ilias Nitsos; Graeme R Polglase; J Jane Pillow; John P Newnham; Alan H Jobe; Suhas G Kallapur
Journal:  Pediatr Res       Date:  2010-09       Impact factor: 3.756

6.  Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age.

Authors:  Olivier Baud; Clémence Trousson; Valérie Biran; Emilie Leroy; Damir Mohamed; Corinne Alberti
Journal:  JAMA       Date:  2017-04-04       Impact factor: 56.272

7.  Evidence of the in vivo esterification of budesonide in human airways.

Authors:  Karen I Maassen van den Brink; Martin Boorsma; A Jeske Staal-van den Brekel; Staffam Edsbäcker; Emiel F Wouters; Lars Thorsson
Journal:  Br J Clin Pharmacol       Date:  2008-04-01       Impact factor: 4.335

8.  Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study.

Authors:  Tsu F Yeh; Hong C Lin; Chien H Chang; Tien S Wu; Bai H Su; Tsai C Li; Suma Pyati; Chang H Tsai
Journal:  Pediatrics       Date:  2008-04-21       Impact factor: 7.124

9.  Brief, large tidal volume ventilation initiates lung injury and a systemic response in fetal sheep.

Authors:  Noah H Hillman; Timothy J M Moss; Suhas G Kallapur; Cindy Bachurski; J Jane Pillow; Graeme R Polglase; Ilias Nitsos; Boris W Kramer; Alan H Jobe
Journal:  Am J Respir Crit Care Med       Date:  2007-07-19       Impact factor: 21.405

10.  Preterm brain injury on term-equivalent age MRI in relation to perinatal factors and neurodevelopmental outcome at two years.

Authors:  Margaretha J Brouwer; Karina J Kersbergen; Britt J M van Kooij; Manon J N L Benders; Ingrid C van Haastert; Corine Koopman-Esseboom; Jeffrey J Neil; Linda S de Vries; Hiroyuki Kidokoro; Terrie E Inder; Floris Groenendaal
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

View more
  7 in total

1.  Surfactant plus budesonide decreases lung and systemic responses to injurious ventilation in preterm sheep.

Authors:  Noah H Hillman; T Brett Kothe; Augusto F Schmidt; Matthew W Kemp; Emily Royse; Erin Fee; Fabrizio Salomone; Michael W Clarke; Gabrielle C Musk; Alan H Jobe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-16       Impact factor: 5.464

Review 2.  Oxygen Toxicity to the Immature Lung-Part I: Pathomechanistic Understanding and Preclinical Perspectives.

Authors:  Yesi Choi; Lisa Rekers; Ying Dong; Lena Holzfurtner; Maurizio J Goetz; Tayyab Shahzad; Klaus-Peter Zimmer; Judith Behnke; Jonas Behnke; Saverio Bellusci; Harald Ehrhardt
Journal:  Int J Mol Sci       Date:  2021-10-12       Impact factor: 5.923

3.  The Change of Cytokines and Gut Microbiome in Preterm Infants for Bronchopulmonary Dysplasia.

Authors:  Zhenjie Zhang; Jingjing Jiang; Zhenghong Li; Weilin Wan
Journal:  Front Microbiol       Date:  2022-03-21       Impact factor: 5.640

Review 4.  The benefits, limitations and opportunities of preclinical models for neonatal drug development.

Authors:  Sarah Campion; Amy Inselman; Belinda Hayes; Costanza Casiraghi; David Joseph; Fabrizio Facchinetti; Fabrizio Salomone; Georg Schmitt; Julia Hui; Karen Davis-Bruno; Karen Van Malderen; LaRonda Morford; Luc De Schaepdrijver; Lutz Wiesner; Stephanie Kourula; Suna Seo; Susan Laffan; Vijay Urmaliya; Connie Chen
Journal:  Dis Model Mech       Date:  2022-04-25       Impact factor: 5.732

5.  Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging.

Authors:  Riccardo Zecchi; Pietro Franceschi; Laura Tigli; Barbara Pioselli; Valentina Mileo; Xabier Murgia; Fabrizio Salomone; Giuseppe Pieraccini; Haruo Usada; Augusto F Schmidt; Noah H Hillman; Matthew W Kemp; Alan H Jobe
Journal:  Pharmaceutics       Date:  2021-06-12       Impact factor: 6.321

6.  The International Week of Surfactant Research: Increasing knowledge about surfactant and unexploited opportunities.

Authors:  Daniele De Luca; Lhoussaine Touqui
Journal:  Biomed J       Date:  2021-07-24       Impact factor: 4.910

Review 7.  Strategies to protect surfactant and enhance its activity.

Authors:  Daniele De Luca; Chiara Autilio
Journal:  Biomed J       Date:  2021-08-05       Impact factor: 4.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.